News29/11/2022
TrialSpark creates Libertas Bio around immunodermatology portfolio
Formation Bio, Inc. →TrialSpark announced acquisition of a majority position in an immunodermatology asset portfolio from Asana BioSciences and the creation of Libertas Bio. The assets included global rights to gusacitinib, ASN008 and preclinical ASN011. Libertas was to develop the portfolio using TrialSpark’s internal technology-enabled capabilities. Financial terms were undisclosed, and the majority-position statement did not identify a numerical ownership percentage. Clinical stages in the announcement describe the programs in November 2022 and are not a current pipeline status assessment.